Format

Send to

Choose Destination
Rejuvenation Res. 2018 Dec;21(6):527-534. doi: 10.1089/rej.2017.2049. Epub 2018 May 30.

Heptamer Peptide Disassembles Native Amyloid in Human Plasma Through Heat Shock Protein 70.

Author information

1
1 Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania.
2
2 The Multiple Sclerosis Research Institute, Philadelphia, Pennsylvania.

Abstract

Proteostasis, which includes the repair and disposal of misfolded proteins, depends, in part, on the activity of heat shock proteins (HSPs), a well-known class of chaperone molecules. When this process fails, abnormally folded proteins may accumulate in cells, tissues, and blood. These species are a hallmark of protein aggregation diseases, but also amass during aging, often in the absence of an identified clinical disorder. We report that a neuroprotective cyclic heptapeptide, CHEC-7, which has been applied systemically as a therapeutic in animal neurodegeneration models, disrupts such aggregates and inhibits amyloidogenesis when added in nanomolar concentrations to human plasma. This effect includes aggregates of amyloid beta (Aβ1-40, 1-42), prominent features of Alzheimer's disease pathology. The activity of endogenous HSP70, a recently discovered target of the peptide, is required as demonstrated by both antibody blocking and application of pifithrin-μ, an HSP70 inhibitor. CHEC-7 is the first high-affinity compound to stimulate HSP70's disaggregase activity and therefore enable this endogenous mechanism in a human systemic environment, increasing the likelihood of a convenient therapy for protein aggregate disease, including age-related failures of protein repair.

KEYWORDS:

Alzheimer's; CHEC peptide; aggregates; amyloid; heat shock protein 70

PMID:
29651925
PMCID:
PMC6310696
[Available on 2019-12-01]
DOI:
10.1089/rej.2017.2049

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center